Objective-The goal of this study was to determine the influence of apolipoprotein A-I (apoA-I) tertiary structure domain properties on the antiatherogenic properties of the protein. Two chimeric hybrids with the N-terminal domains swapped (human-mouse apoA-I and mouse-human apoA-I) were expressed in apoA-I-null mice with adeno-associated virus (AAV) and used to study macrophage reverse cholesterol transport (RCT) in vivo. Methods and Results-The different apoA-I variants were expressed in apoA-I-null mice that were injected with [H 3 ]cholesterol-labeled J774 mouse macrophages to measure RCT. Significantly more cholesterol was removed from the macrophages and deposited in the feces via the RCT pathway in mice expressing mouse-H apoA-I compared with all other groups. Analysis of the individual components of the RCT pathway demonstrated that mouse-H apoA-I promoted ATP-binding cassette transporter A1-mediated cholesterol efflux more efficiently than all other variants, as well as increasing the rate of cholesterol uptake into liver cells. Conclusion-The structural domain properties of apoA-I affect the ability of the protein to mediate macrophage RCT.
jection of AAV8 (1ϫ10 12 genome copies [GC] ) of the appropriate AAV. On day 70 after vector injection, each animal received intraperitoneal injections of 3.0ϫ10 6 [ 3 H]cholesterol-labeled J774 cells. Blood was collected at 6, 24, and 48 hours. Feces were collected from 0 to 48 hours, and after exsanguination at 48 hours, bile and liver samples were collected as previously described. 6, 16 Lecithin-Cholesterol Acyltransferase Activity
The endogenous lecithin-cholesterol acyltransferase (LCAT) cholesterol esterification rate (CER) in whole plasma was measured using a modified Stokke and Norum procedure. [17] [18] [19] Endogenous LCAT activity was expressed as nanomoles of cholesteryl ester (CE) formed per milliliter of plasma during the 30-minute incubation. The exogenous LCAT activity was determined using reconstituted discoidal HDL particles (rHDL) (prepared as described in the Supplemental Materials and Methods, available online at http://atvb.ahajournals.org) at concentrations of 0 to 4 g/mL of cholesterol incubated with recombinant human LCAT at 37°C for 10 to 40 minutes as previously described. 19 
Cellular Cholesterol Efflux
After [ 3 H]cholesterol labeling of J774 cells in which ATP-binding cassette transporter A1 (ABCA1) expression had been upregulated with cAMP in the presence of ACAT inhibitor CP113 818 (2 g/mL), 20 medium containing the appropriate apoA-I acceptor (0 to 20 g/mL) was added. BHK cells in which expression of ATPbinding cassette transporter G1 (ABCG1) was induced by treatment with mifepristone were used to measure cholesterol efflux to rHDL particles (20 g apoA-I/mL). 21 To determine the cholesterol efflux, media were sampled at 4 hours, filtered, and counted by liquid scintillation counting to determine the 
Cholesterol Influx to Cells
Rat Fu5AH hepatoma cells were prepared as described previously 22 and incubated with 20% serum containing [ 3 H]cholesterol and [ 3 H]cholesterylester that was obtained from mice expressing the apoA-I variants and treated with [ 3 H]cholesterol-labeled macrophages for the RCT assay . After 6 hours, the cells were washed 3 times with PBS, the cell lipids were extracted with isopropyl alcohol as previously described, 23 and the levels of 3 H-label were determined. The contribution of SR-BI to influx of HDL cholesterol was assessed by a 2-hour pretreatment of Fu5AH cells with block lipid transport-1 (BLT-1) 24 to inhibit the receptor.
Data Analysis
Data are from representative experiments and are expressed as meanϮSD. Statistical tests for significance were done using an unpaired t test or 1-way ANOVA followed by a Tukey test for pairwise comparisons.
Additional information about methods is available in the Supplemental Materials.
Results
Previous studies of the structures of human and mouse apoA-I, which have a 65% amino acid identity, 25 determined that the N-and C-terminal domains of the 2 proteins had markedly different biophysical properties. 12, 26 These differences in properties are summarized and explained in the Supplemental Materials. Briefly, the N-terminal helix bundle domain of human apoA-I was relatively stable (free energy of stabilization ⌬Gϭ3.4Ϯ0.3 kcal/mol) and exhibited poor lipid binding ability (catalytic efficiency of DMPC vesicle solublizationϭ0.08; Supplemental Table I) , whereas the C-terminal domain was unstable (unfolded) and exhibited high lipid binding ability (catalytic efficiency of DMPC vesicle solubilizationϭ0.20) (see Supplemental Materials). Conversely, the N-terminal helix bundle domain of mouse apoA-I was relatively unstable (⌬Gϭ1.9Ϯ0.1 kcal/mol) and showed good lipid binding ability (catalytic efficiency of DMPC vesicle solubilizationϭ0.30) compared with the human N-terminal domain. The mouse C-terminal domain was disordered and had very poor lipid binding ability because of its highly polar nature. To further study the nature of these differences, 2 human and mouse domain-swap hybrid molecules, human-M apoA-I and mouse-H apoA-I, were created. 12 The combination of the human N-terminal domain and mouse C-terminal domain resulted in a hybrid with a helix bundle of intermediate stability (⌬Gϭ2.3Ϯ0.1 kcal/mol) and relatively poor lipid binding properties (catalytic efficiency of DMPC vesicle solubilizationϭ0.16). In contrast, the combination of the mouse N-terminal domain and human C-terminal domain resulted in an apoA-I molecule that also had intermediate helix bundle stability (⌬Gϭ2.4Ϯ0.1 kcal/mol) but high lipid binding ability (catalytic efficiency of DMPC vesicle solubilizationϭ0.36). The differences in tertiary structure domain characteristics between human and mouse apoA-I present the opportunity to explore the influence of the properties of these domains on the functionality of apoA-I in the RCT pathway.
To investigate what effects these mouse/human hybrid apoA-I had on cholesterol metabolism in vivo , apoA-I-null mice (nϭ6 per group) were injected IP with AAV-expressing WT human apoA-I, WT mouse apoA-I, human-M apoA-I, mouse-H apoA-I, or LacZ control at a dose of 1ϫ10 12 GC. Three weeks after injection, the WT human apoA-I-expressing mice had modestly higher apoA-I levels and significantly higher levels of HDL cholesterol compared with the WT mouse apoA-I-expressing mice (Table) . The human-M apoA-I-expressing animals had apoA-I levels higher than both WT groups but HDL cholesterol levels similar to WT mouse apoA-Iexpressing mice, whereas the mouse-H apoA-I-expressing mice had significantly lower apoA-I and HDL cholesterol levels. Differences between the groups were not attributable to differential gene expression, as hepatic mRNA levels apoA-I were similar among all groups (Supplemental Figure I) .
HDL were isolated via ultracentrifugation and run on a 4% to 20% nondenaturing gradient gel ( Figure 1A ). HDL isolated from WT human apoA-I-and human-M apoA-I-expressing mice formed a single HDL species approximately 9 and 8 nm, respectively, in diameter, whereas HDL from WT mouse apoA-I-and mouse-H apoA-I-expressing mice formed particles approximately 9 and 12 nm in diameter. HDL isolated from LacZ-expressing mice were primarily 12 nm in diameter, with a small amount of HDL that were 9 nm. Gel filtration profiles of serum from apoA-I variant-expressing mice (Supplemental Figure II) showed HDL particle sizes that closely matched the hydrodynamic diameters of the HDL that were isolated and run on 4% to 20% nondenaturing gradient gels ( Figure 1A) . Analysis of the apoprotein composition of HDL isolated from mice expressing WT human apoA-I indicated that the primary protein present was apoA-I along with trace amounts of apoA-II and apoA-IV ( Figure 1B ). For HDL isolated from WT mouse apoA-I-expressing mice, the primary apoprotein was apoA-I, but approximately 20% was apoE. Much like the WT human apoA-I HDL, apoA-I was the only apoprotein present in HDL isolated from human-M apoA-I-expressing mice. HDL isolated from mouse-H apoA-I-expressing mice had equal amounts of apoA-I and apoE along with traces of apoA-II and apoA-IV, whereas HDL isolated from LacZ-expressing mice contained primarily apoE along with traces amounts of apoA-II and apoA-IV. The lipid compositions of the isolated HDL (Supplemental Table   III ) indicate that, on average, the HDL particles from the mice expressing WT mouse apoA-I, mouse-H apoA-I and LacZ contained higher amounts of total cholesterol than the mice expressing WT human apoA-I or human-M apoA-I. This effect is probably due to the presence of the large 12-nm particle that was absent in the WT human apoA-I-and human-M apoA-I-expressing mice. As expected, the relatively large HDL particles with higher cholesterol contents contained lower amounts of surface components (phospholipid and protein).
At weeks 10 after AAV injection, cholesterol-labeled J774 cells were injected for a macrophage RCT study. The [ 3 H]cholesterol counts in plasma, expressed as a percentage of total labeled cholesterol injected, at each time point were significantly higher for WT human apoA-I than for all other groups ( Figure 2A ). WT mouse apoA-I and human-M apoA-I had similar levels of [ 3 H]cholesterol counts in plasma, which were higher than the mouse-H apoA-I and LacZ groups but lower than the WT human A-I group. However, expression of the mouse-H apoA-I variant, which had very low levels of apoA-I and HDL-cholesterol compared with WT human and WT mouse apoA-I (Table) , induced significantly increased transport of macrophage-derived cholesterol into the feces compared with all other groups ( Figure 2B ). This was such a striking result that the entire experiment was repeated with an additional 30 mice. The results from the 2 experiments were very similar, with the counts in the feces from the mouse-H apoA-I-expressing mice being twice that of the counts in the feces of the WT mouse apoA-I-expressing mice in both experiments. [ 3 H]Cholesterol counts in the liver were similar in all groups (data not shown).
To gain further insight into why the mouse-H apoA-I variant had enhanced macrophage RCT compared with all other variants, we investigated several apoA-I-mediated steps in the RCT pathway individually. These steps included ABCA1-and ABCG1-mediated cholesterol efflux from macrophages, the conversion of free cholesterol to cholesterylester by LCAT, and SR-BI-mediated selective uptake into liver cells of cholesterol and cholesterylester from HDL particles. 27 To measure ABCA1-mediated cholesterol efflux, J774 macrophages (the cell type used in the macrophage RCT experiments) were labeled with [ 3 H]cholesterol and then treated with cAMP to upregulate ABCA1. Lipid efflux was then initiated by the addition of the recombinant apoA-I variants at increasing concentrations (0 to 20 g/mL) and the Particle size and apoprotein composition analysis of HDL from mice expressing the human apoA-I variants. ApoA-Inull mice were infected with AAV and bled at 2, 4, and 6 weeks postinfection. HDL were isolated from pooled plasma by ultracentrifugation. A, 10 g of total HDL protein was loaded on a 4% to 20% Tris-glycine nondenaturing gradient gel and stained with Coomassie Brilliant Blue. B, To determine the apoprotein composition of the HDL, 2 g of total protein was analyzed by reducing 8% to 25% SDS-PAGE. H indicates WT human apoA-I; M, WT mouse apoA-I; HM, human-M apoA-I; MH, mouse-H apoA-I.
catalytic efficiencies of the cholesterol efflux reactions were determined from the V max and K m values (Supplemental Table  II) . Mouse-H apoA-I was twice as effective at promoting ABCA1-mediated cholesterol efflux compared with the WT human apoA-I protein and 3.5 times as efficient as the WT mouse apoA-I protein, which was the least effective apoA-I variant ( Figure 3A) . Human-M apoA-I was as effective at promoting ABCA-1-mediated cholesterol efflux as the WT human apoA-I protein and twice as effective as the WT mouse apoA-I protein. The influence of apoA-I structure on ABCG1-mediated cholesterol efflux was measured by incubating BHK cells with discoidal rHDL particles (phospholipid to apoA-I molar ratios of 87Ϯ5/1 and hydrodynamic diameters of 9 to 10 nm; Supplemental Figure V) containing the apoA-I variants at a concentration of 20 g/mL of apoA-I. The results in Figure 3B show that each rHDL was equally proficient at promoting ABCG1-mediated cholesterol efflux.
The next step in the RCT pathway is the conversion of free cholesterol (FC) to CE by LCAT in the plasma. The CER was highest for WT human apoA-I and lowest for mouse-H apoA-I, with the WT mouse apoA-I and human-M apoA-I demonstrating intermediate activities ( Figure 4A ). Corresponding to the reduction in the CER, plasma CE levels in the mouse-H apoA-I-expressing mice were significantly reduced compared with both WT apoA-I-expressing groups ( Figure  4B ). To determine the effects of the apoA-I variants on the kinetic parameters of the LCAT reaction, rHDL (palmitoyloleoyl phosphatidylcholine:cholesterol:apoA-I molar ratios of 86Ϯ5/8Ϯ1/1 and hydrodynamic diameters of 9 to 10 nm) were incubated with recombinant LCAT at 37°C as described in Materials and Methods. The apparent V max of WT human apoA-I was twice that of all other variants, whereas the apparent K m values of all of the reactions were essentially equal (Supplemental Figure III) . The next step in the RCT pathway is SR-BI-mediated selective uptake of cholesterol from HDL in plasma into the liver. Serum samples (which contain [ 3 H]cholesterol and 3 H] cholesterol as described in Materials and Methods. These labeled cells were then treated with cAMP overnight to upregulate ABCA1. The lipid efflux was then initiated by the addition of the recombinant apoA-I variants (0 to 20 g/mL). After a 4-hour incubation, the medium was removed, filtered, and extracted for lipids, and 3 H-radioactivity was determined. The catalytic efficiency (V max /K m ) [(%FC efflux/4 hours)(g apoA-I/mL) Ϫ1 ] was calculated from kinetic parameters generated by fitting the fractional efflux at 4 hours, measured at various concentrations of apoA-I, to the Michaelis-Menten equation. The V max /K m values are plotted as meanϮSD. B, BHK cells were labeled as described in Materials and Methods and treated with mifepristone for 18 hours to upregulate ABCG1. Cholesterol efflux was initiated by the addition of rHDL (20 g/mL apoA-I) containing the recombinant apoA-I variants for 4 hours. *PϽ0.05 compared with WT mouse apoA-I.
[ 3 H]cholesterylester) from the 48-hour time point of the RCT experiment in Figure 2A were diluted in media and applied to Fu5AH rat liver hepatoma cells that express high levels of SR-BI. After the 6-hour incubation with or without BLT-1, which inhibits the activity of the SR-BI transporter, the cells were processed as described in Materials and Methods to determine the amount of label that was taken up from the media into the cells ( Figure 5 ). Serum samples from WT human apoA-I-and WT mouse apoA-I-expressing mice were equally effective at promoting total cholesterol uptake and SR-BI-mediated selective cholesterol uptake into the Fu5AH cells. Serum from both hybrid apoA-I-expressing and LacZ-expressing animals promoted significantly more total uptake of cholesterol compared with serum from either WT human apoA-I-or WT mouse apoA-I-expressing animals. Interestingly, BLT-1 did not inhibit uptake of cholesterol from serum expressing either mouse-H apoA-I or LacZ, indicating that SR-BI mediated selective uptake of cholesterol was not a contributing factor for these groups. A similar experiment using rHDL instead of serum demonstrated that the absence of the human C-terminal domain in the apoA-I molecule significantly decreased SR-BI-mediated influx of cholesterol (Supplemental Figure IV) .
Discussion
As mentioned earlier, the structurally distinct N-and C-terminal domains have markedly different biophysical properties in human and mouse apoA-I (see Supplemental Results). Based on these differences, we postulated that a hybrid apoA-I molecule containing the mouse N-terminal and human C-terminal domains may exhibit enhanced atheroprotective properties. To test this hypothesis, the abilities of 2 domain-swap hybrid apoA-I molecules, human-M apoA-I and mouse-H apoA-I, were compared with the abilities of WT human apoA-I and WT mouse apoA-I to promote macrophage RCT in vivo.
ApoA-I-null mice were injected with AAV expressing either WT human apoA-I, WT mouse apoA-I, human-M apoA-I, mouse-H apoA-I, or LacZ. The apoA-I levels for WT human apoA-I-, WT mouse apoA-I-, and human-M apoA-I-expressing mice were similar, but the apoA-I levels for mouse-H apoA-I-expressing mice were much lower (Table) , despite similar hepatic apoA-I mRNA levels for all groups (Supplemental Figure I ), indicating that mouse-H apoA-I was catabolized faster than the other apoA-I variants. A potential explanation for the increased rate of mouse-H apoA-I turnover is the presence of a relatively high amount of apoE on mouse-H apoA-I HDL ( Figure 1B) , which would promote binding to the low-density lipoprotein (LDL) receptor on hepatocytes. The lower level of apoE on the HDL in animals expressing WT mouse apoA-I caused a smaller reduction in plasma apoA-I concentration relative to WT human apoA-Iexpressing mice (Table) . Once bound to the LDL receptor, the mouse-H apoA-I HDL particle would be internalized and catabolized. In contrast, the selective uptake of HDL cholesterol from particles that do not contain apoE occurs via SR-BI, which does not lead to catabolism of the apoA-I, maintaining its level in plasma and allowing it to participate in additional rounds of RCT.
All of the apoA-I-expressing mice demonstrated increased macrophage RCT compared with the control LacZexpressing mice (Figure 2B ), confirming the ability of apoA-I to promote RCT. However, the mouse-H apoA-I-expressing mice demonstrated a markedly greater increase in fecal excretion of the tracer compared with the other apoA-Iexpressing mice, despite low levels of both apoA-I and HDL-C (RCT levels were increased 2-fold, whereas apoA-I Figure 2A was diluted to 20% with minimal essential medium and incubated with Fu5AH rat hepatoma cells for 6 hours with BLT-1 (Ⅺ) to block SR-BI-mediated influx or without BLT-1 (f). Influx was calculated as described in Materials and Methods. *PϽ0.05 compared with ϩBLT-1 group.
and HDL-C levels were reduced 2.5-and 8.5-fold, respectively, compared with mice expressing WT human apoA-I). The amount of tracer in the plasma (Figure 2A ) of mice expressing the various apoA-I variants mirrored the HDL pool size before the injection of the macrophages (Table) . These results indicate that mouse-H apoA-I is more effective at promoting macrophage RCT than either of the WT apoA-I proteins and that the quality rather than the quantity of the HDL particles is more important in promoting macrophage RCT. The enhanced functionality of the mouse-H apoA-I HDL may be due to a higher fraction of the protein existing as pre-␤-HDL (lipid-free/poor apoA-I), which participates in ABCA1-mediated cellular cholesterol efflux. To gain greater insight into the mechanistic basis for these effects, we dissected the following 3 steps of the RCT pathway: ABCA1-mediated cholesterol efflux, LCAT-mediated conversion of FC to CE, and the uptake of cholesterol into the liver.
The catalytic efficiencies (V max /K m ) of the apoA-I variants in supporting ABCA1-mediated cholesterol efflux from J774 macrophages were determined, and the value for mouse-H apoA-I was 2-fold higher than WT human apoA-I and 3.5-fold higher than WT mouse apoA-I ( Figure 3A ). This increase in catalytic efficiency was likely due to the enhanced ability of mouse-H apoA-I to interact with lipids. When the ability of the apoA-I variants to interact with and solubilize DMPC vesicles was studied, it was determined that mouse-H apoA-I had the highest catalytic efficiency, 16% higher than WT human apoA-I and 2-fold higher than WT mouse apoA-I (Supplemental Table I ). According to the exovesiculation model of apoA-I interaction with ABCA1, there are 3 steps involved in the ABCA1-mediated efflux of cellular cholesterol and phospholipids. 28 First, apoA-I binds to ABCA1 and enhances net phospholipid translocation to the exofacial leaflet which causes unequal lateral packing densities in the 2 leaflets of the phospholipid bilayer. Second, the resulting membrane strain is relieved by the creation of an exovesiculated lipid domain. This highly curved membrane promotes high affinity binding of apoA-I. Third, the lipid-bound apoA-I then spontaneously solubilizes the exovesiculated domains to form nascent HDL particles. It is this third and final step that is rate limiting for efflux. On this basis, the enhanced ability of mouse-H apoA-I to solubilize lipid and thereby efficiently mediate ABCA1-mediated lipid efflux from macrophages (combined with a likely higher level of the circulating protein being in the lipid-free [or lipidpoor] state) presumably contributes to this hybrid apoA-I promoting RCT so effectively. The abilities of rHDL particles to promote ABCG1-mediated cholesterol efflux were similar for all of the apoA-I variants ( Figure 3B ), suggesting that variations in apoA-I domain structure do not affect acceptor particle efficiency when the variants are present in discoidal rHDL particles of similar size (9 to 10 nm hydrodynamic diameter).
The next step of the RCT pathway, the conversion of FC to CE by LCAT in the plasma, was measured using wellestablished methods. 18 The results demonstrated that both hybrid apoA-I variants were unable to activate LCAT to the same extent as the WT proteins (Figure 4) . Interestingly, if the CER of the mouse-H apoA-I-expressing sample is normalized to apoA-I concentration, taking into account the low levels of mouse-H apoA-I (Table) , mouse-H apoA-I is as efficient as WT mouse apoA-I at activating LCAT but still not as efficient as WT human apoA-I. The reductions in CER are likely due to variations in HDL particle size distribution and changes in structure of the apoA-I on the HDL particles, altering the manner in which apoA-I and LCAT interact as LCAT binds to a HDL particle. The relationship between LCAT activity and RCT or cardiovascular disease is uncertain at this time, with several studies concluding that higher levels of LCAT activity are associated with increased incidences of cardiovascular disease, 29, 30 whereas others describe either a negative correlation or no correlation between LCAT activity and cardiovascular disease or RCT. [31] [32] [33] In our experiments, the 2 groups with the lowest CER, mouse-H apoA-Iand LacZ-expressing mice, had the highest and lowest amount of 3 H radioactivity in the feces, respectively ( Figure  2B ). It follows that LCAT activity does not determine overall macrophage RCT activity. 15, 33 The third step of RCT is the uptake of plasma HDL cholesterol into the liver. Sera from WT human apoA-I-and WT mouse apoA-I-expressing animals were equally efficient at promoting total cholesterol uptake into hepatoma cells, whereas sera from human-M apoA-I-, mouse-H apoA-I-, and LacZ-expressing mice were all more efficient ( Figure 5) . A factor contributing to this effect may be the apoE on the HDL from mouse-H apoA-I-and LacZ-expressing mice ( Figure  1B) , which promotes cholesterol delivery to the liver via the LDL receptor, which mediates the endocytosis of apoEcontaining lipoproteins. The low level of apoE in the HDL from mice expressing WT mouse apoA-I is apparently insufficient to mediate such an effect. In addition, the lipoproteins in serum from mice expressing mouse-H apoA-I and LacZ have a higher FC-to-phospholipid ratio than lipoproteins from the serum of the other 3 groups (calculated from data in the Table) . This increases the FC concentration gradient between the HDL and cell plasma membrane, which can increase the cellular uptake of HDL FC by passive diffusion. 34 However, the increased rate of cholesterol uptake from serum that contains human-M apoA-I cannot be explained in this fashion. Interestingly, the inhibition of SR-BI selective uptake with BLT-1 did not affect the uptake of cholesterol from serum containing either mouse-H apoA-I or LacZ, indicating that for these samples, SR-BI did not contribute significantly to cholesterol delivery from HDL to the liver cells. Any contribution of SR-BI-mediated selective uptake of HDL cholesterol in these serum samples may be masked by the contribution of lower density lipoproteins; the ratio of HDL cholesterol to total cholesterol (0.39 to 0.43, calculated from data in the Table) is relatively low compared with the serum containing WT human apoA-I, WT mouse apoA-I, or human-M apoA-I (0.58 to 0.77). The apoBcontaining lipoproteins may play a major role in the cholesterol uptake from serum containing mouse-H apoA-I or LacZ. Interestingly, when rHDL were used as a substrate in the same SR-BI-mediated cholesterol uptake system (Supplemental Figure IV) , those variants that lacked the human C-terminal domain (WT mouse apoA-I and human-M apoA-I) showed a significant decrease in selective uptake. These results indicate that when all other factors, such as apoB-containing lipoproteins, are removed, a more hydrophobic apoA-I C-terminal domain increases SR-BI-mediated selective uptake of HDL cholesterol.
Despite the lower plasma apoA-I and HDL-C levels, expression of mouse-H apoA-I gives rise to more efficient macrophage RCT than does expression of either WT human apoA-I or WT mouse apoA-I. The altered properties of the mouse-H apoA-I hybrid, in particular its increased lipid affinity and the presence of apoE on mouse-H apoA-I HDL (which is mediated by apoE-resident apolipoprotein interactions, 35 in this case between mouse apoE and the mouse apoA-I N-terminal helix-bundle domain), led to several major changes in the functionality in vivo of the apoA-I molecule and the HDL particles containing it. It seems likely that this apoA-I variant increases the rate of ABCA1-mediated macrophage cholesterol efflux and nascent HDL particle formation, as well as increasing the rate of cholesterol uptake by liver via the LDL receptor because of the presence of apoE, thereby enhancing the flux of cholesterol along the RCT pathway.
Overall, these results show that the tertiary structure domain properties of apoA-I affect the ability of the protein to mediate macrophage RCT. The fact that replacement of the N-terminal helix bundle domain in the human apoA-I with the mouse apoA-I counterpart causes a gain of function with respect to macrophage RCT suggests that engineering some destabilization into the N-terminal helix bundle domain or an increase in hydrophobicity of the C-terminal domain of human apoA-I would enhance the antiatherogenicity of this protein.
